Dactinomycin is an antineoplastic antibiotic used to treat various cancers, including Wilms tumor and rhabdomyosarcoma. It works by intercalating DNA, thereby inhibiting RNA synthesis. It is grouped under the following drug class(es): Antineoplastic agents and Cytotoxics. Its therapeutic use is listed as anti-cancer agents and antineoplastics. The directory classifies it as a commercial API with a peptide source/manufacturing origin. Other names for this substance include Actinomycin D, Oncostatin K and Cosmegen. Its PubChem CID is 457193.
Dactinomycin
| CAS No | 50-76-0 |
|---|---|
| Molecular Formula | C62H86N12O16 |
| Molecular Weight | 1255.4 g/mol |
| Synonyms | 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Dactinomycin is an antineoplastic antibiotic used to treat various cancers, including Wilms tumor and rhabdomyosarcoma. It works by intercalating DNA, thereby inhibiting RNA synthesis.
The listed CAS number is 50-76-0.
The listed molecular formula is C62H86N12O16.
The listed molecular weight is 1255.4 g/mol.
2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide.
The source lists Actinomycin D, Oncostatin K and Cosmegen.